Scientific Abstracts poorly understood. The study of lipid profiles in RA has been biased towards lipoprotein levels, whereas those of triglycerides (TG) and lipoprotein functionality have been neglected. Objectives: since recent findings point to an emerging role for TG and TG-rich lipoproteins (TRL) on inflammation, we aimed to evaluate a combined lipid profile characterized by high TG and low HDL levels (TG high HDL low ) in RA. Methods: lipid profiles were analyzed in 113 RA patients, 113 healthy controls (HC) and 27 dyslipemic subjects (DL). A group of 13 biological-naïve RA patients was prospectively followed for 3 months upon TNFα-blockade. Serum levels of inflammatory mediators were assessed by immunoassays. PON1 activity and Total Antioxidant Capacity (TAC) were quantified in serum. PON1 rs662 status was evaluated by RT-PCR Results: the prevalence of the TG high HDL low profile was similar among RA patients (29/113), HC (30/113) and DL (11/27), linked to higher TRL levels in all groups. However, this profile was associated with increased CRP (p=0.012), TNFα (p=0.004), MCP-1 (p=0.004), IP-10 (p=0.018) and leptin (p<0.001) serum levels in RA, where decreased PON1 activity and TAC were found (both p<0.001). TRL serum levels were positively correlated to inflammatory mediators, whereas a negative association was found for PON1 activity (r=-0.203, p=0.036). These findings remain after excluding patients with previous CV events or those under statins. No associations were observed in the HC and DL groups. When RA patients were stratified by PON1 rs662 status, these associations were restricted to the low activity genotype (QQ) (TNFα: p=0.002, MCP-1: p=0.013, EGF: p=0.047, IP-10: p=0.018 and leptin: p=0.002), whereas no effect of the lipid profile was observed in those harboring the QR or RR genotypes (all p>0.050). As expected, QQ-patients exhibited a lower PON1 activity compared to the other genetic variants (both p<0.010). The TG high HDL low prevalence was related to a decreased anti-TNFα usage in the cross-sectional sample (p=0.004 Background: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients (1). Hydroxychloroquine (HCQ) has been shown to improve major outcomes like survival rates in other inflammatory diseases, like systemic lupus (2). Objectives: The aim of our study was to assess currently available literature on the cardiovascular impact of hydroxychloroquine (HCQ) in patients with RA. Methods: We systematically searched literature (via Pubmed, Embase and abstracts from recent ACR and EULAR congresses) for studies evaluating the effects of HCQ, wether in monotherapy or in combination with other conventional synthetic disease modifying antirheumatic drugs (csDMARDs) on cardiovascular outcomes or known risk factors for CVD in RA patients (lipid profiles, diabetes incidence, insulin resistance and incidence of CVD). A meta-analysis was performed with Review Manager Software, with random effects models, whenever methodologically possible and relevant. Data were extracted by one investigator and independently checked by another. Results: The literature search revealed 185 articles and abstracts of potential interest, and further examination resulted in 16 studies fulfilling required criteria for preplanned analyses regarding the cardiovascular impact of HCQ in RA. For lipid profiles, the mean difference (mg/dL) between HCQ users versus nonusers was -9,82 (95% confidence interval [95% CI] 14.03; 5.60) for total cholesterol, -10.61 [14.17;7.04] for low density lipoprotein, -19.15 [27.20; 11.10] for triglycerides and +4.13 [2.22;6.04] for high density lipoprotein (figure 1); with respectively a decrease (mg/dL) of 13.15 [20.96; 5.34], 12.35 [20.14; 4.36], 12.54 [28.94; 3.86] and an increase of 1.67 [0.96, 4.31] after HCQ initiation. Diabetes incidence was reduced in "HCQ ever users" versus "patients who never used HCQ" with a hazard ratio of 0.59 [0.49; 0.70]. In addition, HCQ seems to decrease insulin resistance and incidence of cardiovascular events but data were too scarce for meta-analysis. Conclusions: Beside its limited efficacy on disease activity, this study supports the interest of HCQ on lipid profiles, and diabetes incidence, and to a lesser extent on cardio-vascular events and insulin resistance in RA patients. Therefore, this study suggests that HCQ may be of some interest in RA, in combination with other csDMARDS.
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